company background image

Albireo Pharma NasdaqCM:ALBO Stock Report

Last Price


Market Cap







28 Sep, 2022


Company Financials +
ALBO fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

ALBO Stock Overview

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.

Albireo Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Albireo Pharma
Historical stock prices
Current Share PriceUS$19.57
52 Week HighUS$37.63
52 Week LowUS$16.02
1 Month Change10.69%
3 Month Change-1.46%
1 Year Change-35.13%
3 Year Change3.44%
5 Year Change-9.23%
Change since IPO34.04%

Recent News & Updates

Sep 22

Albireo gains on royalty agreement for pruritus therapy

Albireo Pharma, Inc. (NASDAQ:ALBO) added ~7% in the morning hours Thursday after the biotech focused on liver diseases announced an agreement with asset manager Sagard Healthcare Partners to sell royalties from the company's FDA-approved pruritus therapy Bylvay. Per the terms, Sagard will provide ALBO with a $115M upfront payment in return for a mid-single digit average royalty rate on Bylvay's global annual net revenues. The total royalties are capped at 1.6x of invested capital if repaid before Dec. 31, 2028, and 2.0x if repaid after that. The agreement ends with the achievement of the capped amount. The deal allows the company to extend its cash runway beyond at least 2024 when topline data is expected from the BOLD Phase 3 study for Bylvay in patients with biliary atresia. "These additional resources allow us to build Bylvay into a billion-dollar product and advance the development of our early asset pipeline," ALBO Chief Executive Ron Cooper remarked.

Sep 06

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

Albireo Pharma (NASDAQ:ALBO) said the Italian Medicines Agency has enabled reimbursed access to Bylvay (odevixibat) to treat all types of patients with progressive familial intrahepatic cholestasis (PFIC) in Italy. PFIC is a rare progressive, liver disease. Bylvay was granted Full Therapeutic Innovation status by Agenzia Italiana del Farmaco (AIFA), a designation for some products with unmet need and added clinical benefit, Albireo said in a Sept. 6 press release.

Aug 23
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Market forces rained on the parade of Albireo Pharma, Inc. ( NASDAQ:ALBO ) shareholders today, when the analysts...

Shareholder Returns

ALBOUS BiotechsUS Market

Return vs Industry: ALBO underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: ALBO underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is ALBO's price volatile compared to industry and market?
ALBO volatility
ALBO Average Weekly Movement13.2%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ALBO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ALBO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

n/a130Ron Cooper

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.

Albireo Pharma Fundamentals Summary

How do Albireo Pharma's earnings and revenue compare to its market cap?
ALBO fundamental statistics
Market CapUS$383.82m
Earnings (TTM)-US$36.26m
Revenue (TTM)US$51.22m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALBO income statement (TTM)
Cost of RevenueUS$2.37m
Gross ProfitUS$48.86m
Other ExpensesUS$85.12m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.85
Gross Margin95.38%
Net Profit Margin-70.79%
Debt/Equity Ratio8.9%

How did ALBO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ALBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALBO?

Other financial metrics that can be useful for relative valuation.

ALBO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ALBO's PS Ratio compare to its peers?

ALBO PS Ratio vs Peers
The above table shows the PS ratio for ALBO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.6x
PTGX Protagonist Therapeutics
KPTI Karyopharm Therapeutics
IDYA IDEAYA Biosciences
SLNC.F Silence Therapeutics
ALBO Albireo Pharma

Price-To-Sales vs Peers: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (12.6x).

Price to Earnings Ratio vs Industry

How does ALBO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the US Biotechs industry average (12.7x)

Price to Sales Ratio vs Fair Ratio

What is ALBO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALBO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ratio22.5x

Price-To-Sales vs Fair Ratio: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (22.5x).

Share Price vs Fair Value

What is the Fair Price of ALBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Albireo Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALBO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALBO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALBO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALBO's revenue (58% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: ALBO's revenue (58% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Albireo Pharma performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALBO is currently unprofitable.

Growing Profit Margin: ALBO is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.

Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: ALBO has a negative Return on Equity (-31.9%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Albireo Pharma's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALBO's short term assets ($195.8M) exceed its short term liabilities ($43.6M).

Long Term Liabilities: ALBO's short term assets ($195.8M) exceed its long term liabilities ($71.7M).

Debt to Equity History and Analysis

Debt Level: ALBO has more cash than its total debt.

Reducing Debt: ALBO's debt to equity ratio has increased from 2.6% to 8.9% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALBO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALBO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 38.9% each year.

Discover healthy companies


What is Albireo Pharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Albireo Pharma Dividend Yield vs Market
How does Albireo Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (Albireo Pharma)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Albireo Pharma)n/a

Notable Dividend: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALBO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALBO's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALBO has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ron Cooper (59 yo)





Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

CEO Compensation Analysis

Ron Cooper's Compensation vs Albireo Pharma Earnings
How has Ron Cooper's remuneration changed compared to Albireo Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$6mUS$590k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$3mUS$570k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$3mUS$551k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$4mUS$530k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$2mUS$460k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$4mUS$400k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$352kUS$221k


Compensation vs Market: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD2.92M).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ALBO's management team is considered experienced (4 years average tenure).

Board Members

Experienced Board: ALBO's board of directors are considered experienced (5.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALBO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders273,7281.4%
General Public412,1772.1%
VC/PE Firms2,360,13912.0%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 86.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Perceptive Advisors LLC
Federated Hermes, Inc.
State Street Global Advisors, Inc.
1,424,343$27.9m56.74%no data
Chicago Capital, LLC
BlackRock, Inc.
1,212,620$23.7m5.35%no data
The Vanguard Group, Inc.
993,970$19.5m1.67%no data
Franklin Resources, Inc.
Medical Strategy GmbH, Asset Management Arm
Tang Capital Management, LLC
ArrowMark Colorado Holdings, LLC
Decheng Capital LLC
Prosight Management, LP
Rice Hall James & Associates, LLC
Nicholas Investment Partners, L.P.
Dimensional Fund Advisors LP
388,857$7.6m7.7%no data
Geode Capital Management, LLC
328,701$6.4m-2.61%no data
GW&K Investment Management, LLC
Privium Fund Management BV
MAI Capital Management, LLC
J. Goldman & Co., L.P.
Platinum Investment Management Limited
Northern Trust Global Investments
181,432$3.6m-1.7%no data
Citadel Advisors LLC
121,521$2.4m23.99%no data
Morgan Stanley, Investment Banking and Brokerage Investments
116,968$2.3m117.06%no data
Birchview Capital, LP

Company Information

Albireo Pharma, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Albireo Pharma, Inc.
  • Ticker: ALBO
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$383.817m
  • Shares outstanding: 19.61m
  • Website:

Number of Employees


  • Albireo Pharma, Inc.
  • 10 Post Office Square
  • Suite 1000
  • Boston
  • Massachusetts
  • 2109
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BDQMDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2016
ALBONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2016
ALBO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.